Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

By Ludwig Burger and Michael Erman (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with ...

Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...